Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study

The conditions and outcomes of Japanese patients with prostate cancer who developed PSA failure after radical prostatectomy (RP), and who were treated via salvage radiotherapy (S-RT), were surveyed. Clinical data on S-RT were gathered in questionnaires completed by facilities participating in the Ja...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radiation research 2015-07, Vol.56 (4), p.750-756
Main Authors: Mizowaki, Takashi, Aoki, Manabu, Nakamura, Katsumasa, Yorozu, Atsunori, Kokubo, Masaki, Karasawa, Katsuyuki, Kozuka, Takuyo, Nakajima, Nobuaki, Sasai, Keisuke, Akimoto, Tetsuo
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Cancer patients
Complications and side effects
Disease-Free Survival
Humans
Japan - epidemiology
Longitudinal Studies
Male
Middle Aged
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - prevention & control
Oncology
Patient outcomes
Postoperative Period
Prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy - mortality
Prostatic Neoplasms - blood
Prostatic Neoplasms - mortality
Prostatic Neoplasms - therapy
Radiation (Physics)
Radiotherapy
Radiotherapy, Adjuvant - mortality
Radiotherapy, Conformal - mortality
Retrospective Studies
Salvage Therapy - mortality
Sentinel Surveillance
Surgery
Surveys
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The conditions and outcomes of Japanese patients with prostate cancer who developed PSA failure after radical prostatectomy (RP), and who were treated via salvage radiotherapy (S-RT), were surveyed. Clinical data on S-RT were gathered in questionnaires completed by facilities participating in the Japanese Radiation Oncology Study Group. S-RT was defined as external-beam radiotherapy delivered to the prostate beds of patients with prostate cancer who had eventually developed PSA failure, although their PSA values had at one stage attained levels 0.3 ng/ml (57.5% vs 40.5%, P = 0.027). In Japan, hormonal therapy is combined with S-RT in ∼40% of cases. The 5-year PRFS and CFFS rates of cases treated via S-RT alone were 50.1% and 90.1%, respectively. A PSA value of 0.3 ng/ml served as a significant cut-off for prediction of PRFS.
ISSN:0449-3060
1349-9157
DOI:10.1093/jrr/rrv027